Email This Release
Resumen: Samsung Bioepis obtiene aprobación regulatoria para ONTRUZANT®, el primer biosimilar de trastuzumab de Europa
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words: